# Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

> **NCT05112159** · PHASE1 · COMPLETED · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 76 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** IPG1094 300 mg SAD
- **DRUG:** IPG1094 600 mg SAD
- **DRUG:** IPG1094 900 mg SAD
- **DRUG:** IPG1094 1200 mg SAD
- **DRUG:** IPG1094 600 mg MAD QD
- **DRUG:** IPG1094 200 mg MAD BID
- **DRUG:** IPG1094 300 mg MAD BID
- **DRUG:** IPG1094 300 mg Fed-Fasted
- **DRUG:** IPG1094 300 mg Fasted-Fed
- **DRUG:** IPG1094 100 mg SAD

## Key facts

- **NCT ID:** NCT05112159
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-27
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-07-25
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112159, "Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05112159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*